Trial Profile
Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Monoclonal antibody 3F8 (Primary)
- Indications Neuroblastoma; Solid tumours
- Focus Adverse reactions
- 03 Aug 2023 Status changed from active, no longer recruiting to completed.
- 24 Aug 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2023.
- 24 Aug 2022 Planned primary completion date changed from 1 Aug 2022 to 1 Aug 2023.